Literature DB >> 24362694

Live-attenuated respiratory syncytial virus vaccines.

Ruth A Karron1, Ursula J Buchholz, Peter L Collins.   

Abstract

Live-attenuated respiratory syncytial virus (RSV) vaccines offer several advantages for immunization of infants and young children: (1) they do not cause vaccine-associated enhanced RSV disease; (2) they broadly stimulate innate, humoral, and cellular immunity, both systemically and locally in the respiratory tract; (3) they are delivered intranasally; and (4) they replicate in the upper respiratory tract of young infants despite the presence of passively acquired maternally derived RSV neutralizing antibody. This chapter describes early efforts to develop vaccines through the classic methods of serial cold-passage and chemical mutagenesis, and recent efforts using reverse genetics to derive attenuated derivatives of wild-type (WT) RSV and to develop parainfluenza vaccine vectors that express RSV surface glycoproteins.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24362694      PMCID： PMC4794267          DOI： 10.1007/978-3-642-38919-1_13

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


  65 in total

1.  The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription.

Authors:  A Bermingham; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.

Authors:  Emmalene J Bartlett; Emerito Amaro-Carambot; Sonja R Surman; Jason T Newman; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2005-09-07       Impact factor: 3.641

3.  The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations.

Authors:  K Juhasz; S S Whitehead; C A Boulanger; C Y Firestone; P L Collins; B R Murphy
Journal:  Vaccine       Date:  1999-03-17       Impact factor: 3.641

4.  Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.

Authors:  S S Whitehead; A Bukreyev; M N Teng; C Y Firestone; M St Claire; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

5.  Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.

Authors:  C Y Firestone; S S Whitehead; P L Collins; B R Murphy; J E Crowe
Journal:  Virology       Date:  1996-11-15       Impact factor: 3.616

6.  Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Authors:  Ruth A Karron; Peter F Wright; Robert B Belshe; Bhagvanji Thumar; Roberta Casey; Frances Newman; Fernando P Polack; Valerie B Randolph; Anne Deatly; Jill Hackell; William Gruber; Brian R Murphy; Peter L Collins
Journal:  J Infect Dis       Date:  2005-03-01       Impact factor: 5.226

7.  A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.

Authors:  S S Whitehead; C Y Firestone; P L Collins; B R Murphy
Journal:  Virology       Date:  1998-08-01       Impact factor: 3.616

8.  Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.

Authors:  S S Whitehead; C Y Firestone; R A Karron; J E Crowe; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV.

Authors:  H Jin; D Clarke; H Z Zhou; X Cheng; K Coelingh; M Bryant; S Li
Journal:  Virology       Date:  1998-11-10       Impact factor: 3.616

10.  Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization.

Authors:  J E Crowe; P T Bui; G R Siber; W R Elkins; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1995-06       Impact factor: 3.641
View more
  64 in total

Review 1.  What Are the Most Powerful Immunogen Design Vaccine Strategies? A Structural Biologist's Perspective.

Authors:  Peter D Kwong
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 2.  Respiratory Syncytial Virus Infection: An Illness for All Ages.

Authors:  Edward E Walsh
Journal:  Clin Chest Med       Date:  2016-12-27       Impact factor: 2.878

3.  Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Authors:  Bo Liang; Sonja Surman; Emerito Amaro-Carambot; Barbora Kabatova; Natalie Mackow; Matthias Lingemann; Lijuan Yang; Jason S McLellan; Barney S Graham; Peter D Kwong; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

Review 4.  Ongoing developments in RSV prophylaxis: a clinician's analysis.

Authors:  Fariba Rezaee; Debra T Linfield; Terri J Harford; Giovanni Piedimonte
Journal:  Curr Opin Virol       Date:  2017-05-10       Impact factor: 7.090

5.  Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children.

Authors:  Elizabeth J McFarland; Ruth A Karron; Petronella Muresan; Coleen K Cunningham; Charlotte Perlowski; Jennifer Libous; Jennifer Oliva; Patrick Jean-Philippe; Jack Moye; Elizabeth Schappell; Emily Barr; Vivian Rexroad; Laura Fearn; Mikhaela Cielo; Andrew Wiznia; Jaime G Deville; Lijuan Yang; Cindy Luongo; Peter L Collins; Ursula J Buchholz
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

Review 6.  Molecular and genetic inflammation networks in major human diseases.

Authors:  Yongzhong Zhao; Christian V Forst; Camil E Sayegh; I-Ming Wang; Xia Yang; Bin Zhang
Journal:  Mol Biosyst       Date:  2016-07-19

7.  Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.

Authors:  Mohamed A Farrag; Haitham M Amer; Peter Öhlschläger; Maaweya E Hamad; Fahad N Almajhdi
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

8.  Zinc binding activity of human metapneumovirus M2-1 protein is indispensable for viral replication and pathogenesis in vivo.

Authors:  Hui Cai; Yu Zhang; Yuanmei Ma; Jing Sun; Xueya Liang; Jianrong Li
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

9.  Vaccination strategies against respiratory syncytial virus.

Authors:  Dan Yamin; Forrest K Jones; John P DeVincenzo; Shai Gertler; Oren Kobiler; Jeffrey P Townsend; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

10.  Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.

Authors:  Natalie Mackow; Emérito Amaro-Carambot; Bo Liang; Sonja Surman; Matthias Lingemann; Lijuan Yang; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.